The Epidemiology and Risk Assessment of Mucositis
Publisher
Springer Healthcare Ltd.
Reference31 articles.
1. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005; 13: 219–227.
2. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110–1120.
3. Treister N, Sonis S. Oral mucositis. In: Ettinger DS, ed. Cancer and Drug Discovery Development: Supportive Care in Cancer Therapy. Totowa, NJ: Humana Press. 2008;193–211.
4. Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;261519–1525.
5. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598.